Curis (CRIS) stock

Market cap $789KShares as of Aug 11

$0.38

-2.33%

As of Monday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score CRIS. It is too small, priced too low, and too thinly traded for a fair Quality Score.

Healthcare · Biotech

Follow CRIS's trial news. Pro members can get an alert when Curis files news, and see its trials, share raises, and its CEO's filings.

Get an alert when CRIS files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,191 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

What's next for CRIS, and how long its cash lasts

Its trials

A trial underway: CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)Phase 1/2 · Recruiting · 152 people · main data estimated Jul 2027 · NCT03328078

1 more trial, 34 filings, for Pro members.

Cash runway

The company says its cash lasts into 2027 (8-K, Jan 8).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Feb 8, 2024)
At-the-market share sales program (424B5, filed Aug 8, 2025)

For Pro members: 5 raises and their amounts, and the share count against a year ago.

Insiders

Director Kenneth I Kaitin bought 10,000 shares on Mar 31.

From Form 4: open-market buys and sales only.

Get an alert when James Dentzer buys or sells

For Pro members: every trade, and James Dentzer’s 6 filings and quotes.

Get an alert when CRIS files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

CRIS's latest filings

An agreement8-K, filed Oct 19
Quarterly report10-Q, filed Aug 14
Prospectus for a sale of securities424B4, filed Aug 13

21 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why CRIS isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. CRIS is worth about $789K, trades at $0.38, and about 253,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.